Pfizer By The Numbers: 800 R&D Job Cuts But At Least Two Dozen Phase III Projects By Year End
This article was originally published in The Pink Sheet Daily
Executive Summary
Research chief Mackay says Pfizer's research portfolio has been extensively reviewed by both internal and outside experts